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Curcumin is the active component of the Indian spice turmeric, known since ancient times for medicinal properties. 
Extensive research in the last two to three decades has confirmed its promising pharmacological properties such as anti-cancer, 
anti-oxidant, anti-inflammatory etc., leading to several ongoing/completed clinical trials. Curcumin has three reactive functional 
groups: one diketone moiety, and two phenolic groups. Curcumin interacts with several biomolecules through non-covalent and 
covalent binding. However, the properties limiting its potential are low bioavailability and fast degradation. The metabolites as 
well as degradation products of curcumin show biological activities but not as much as curcumin. To overcome these 
limitations, new analogues with modifications on both o-methoxy group and the diketo structures of curcumin have been 
developed. Of several analogues, dimethyl curcumin, where the phenolic OH is absent showed better anti-tumor activity. Also, 
the isoxazole and pyrazole derivatives of curcumin, derivatized at the diketo moiety have been investigated in our group. 
Hispolon, which is a half curcumin analogue also showed interesting cellular activity. Here in the present manuscript, the 
comparative cytotoxic effect of curcumin and some of these derivatives in cancer cells is presented. The results indicated that 
specific structural modifications on curcumin can be adopted to finetune its desired anticancer activity.  
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Curcumin, the active principle of Curcuma species has 
been one of the highly researched molecules1-5. There 
are at least 200 known varieties of curcuma species all 
over the world. Even before curcumin was 
investigated, turmeric, or Curcuma longa, was known 
to Indians and Chinese as a medicinal herb as 
mentioned in Indian scriptures, Ayurveda and other 
related documents6. To the Europeans and Americans, 
turmeric is not much known, the latest, one can trace 
back is the mention of it by Marcopolo in his travel 
logs around 13th century6. India is the major producer 
of turmeric6. Apart from Curcuma longa, other known 
Curcuma species are Curcuma zedoaria, Curcuma 
aromatic etc. Curcumin content in curcuma species 
varies with the soil, location, climatic conditions etc. 
Although curcumin was isolated from turmeric 
nearly two centuries ago, there were only a few reports 
till the 1970s on its chemical structure, synthesis, and 
biological activity4. However, after reports on its 
potential anticancer effect were known in 90s, the pace 
of curcumin research has grown rapidly1-5 with more 
than 18000 citations to date. While the majority of 
researchers have been pursuing the medicinal aspects, a 
few others were reporting chemistry, development of 
new analogues and recently its formulations. Curcumin 
research has become one of the most favorite subjects 
for all the branches of chemistry, including organic, 
inorganic, physical and analytical chemists1-5. 
Important findings are extraction methodologies, 
synthesis of curcumin derivatives, preparation of metal 
chelates with modified biochemical activities, 
understanding molecular mechanisms on its 
interactions with biomolecules and use of its unique 
spectroscopic properties to identify and quantitatively 
————— 
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estimate trace elements1-7. Other important areas of 
chemistry research are its reactivity with reactive 
oxygen species (ROS), degradation and formation of 
nanoconjugates and formulations4,8.  
The extensive biological research on curcumin has 
confirmed its anti-inflammatory, chemopreventive 
and therapeutic potential against varieties of cancers1-3,5. 
Free radicals formed from reactive oxygen and 
nitrogen species act as key players in the initiation 
and progression of tumor cells and enhance their 
metastatic potential9. Some of the factors leading to 
anti-cancer effects of curcumin are inhibition of 
different types of enzyme kinases or signal 
transducers, transcription factors and cytokines and 
induction of apoptosis in cancer cells1-3,5. Currently, 
curcumin is being examined in the clinic against 
several diseases such as multiple myeloma, pancreatic 
cancer, colon cancer, head and neck cancers, liver and 
skin diseases, metabolic disorders, neurological 
diseases etc10.  
Curcumin supplementation is recommended 
against many chronic diseases. Curcumin has been 
reported to be safe for humans even in gram 
quantities11. This has led to a big market for curcumin 
all over the world and curcumin nutraceuticals, 
curcumin based food products and cosmetics are 
being sold across the counters5. 
 
Demand for Ayurvedic medicinal formulations has 
been gaining momentum in several developed 
countries as well. As a result of all these, the global 
curcumin market size has reached USD 23552.9 
thousand in 2016 and is projected to see a yearly 
growth rate of 13.3%12. Some of the side effects 
reported with curcumin administration are its 
influence in inhibiting blood clotting, aggravating 
gallstone problems, iron metabolism, liver function 
etc13. 
The major limitation restricting the therapeutic 
usage of curcumin is its stability and low 
bioavailability3,7,14,15. Even after administration in 
gram quantities, only a nanogram of curcumin is 
found in the plasma. Due to its hydrophobic nature, 
curcumin is poorly soluble in neutral water. It 
undergoes fast degradation in solution3,4,7. The 
stability of curcumin is crucial to maintain its 
physiological activities. The decomposition of 
curcumin is pH-dependent and it degrades more 
rapidly at neutral-basic conditions4,7. The presence of 
10% fetal calf serum in cell culture medium and 
human blood improves the hydrolytic stability of 
curcumin, and the addition of anti-oxidants such as 
ascorbic acid, N-acetylcysteine and glutathione 
(GSH) slows the degradation of curcumin3,4,7. 
Curcumin is also sensitive to light and is rapidly 
decolorized upon exposure to UV light7. 
Curcumin also participates in a variety of chemical 
reactions in biological systems. Important among 
these are the hydrogen donation reactions with ROS 
leading to oxidation of curcumin, reversible and 
irreversible nucleophilic addition reactions, 
hydrolysis, degradation, and enzymatic reactions4,16-18. 
The hydrogen bonding and hydrophobicity of 
curcumin, arising from the aromatic and tautomeric 
structures along with the flexibility of the linker group 
are responsible for the non-covalent interactions  
with proteins and other biomolecules4. The ,  
β unsaturated β-diketone moiety covalently interacts 
with protein thiols, through Michael reaction4,7. The 
β-diketo group forms chelates with transition metals, 
thereby reducing the metal induced toxicity and 
some of the metal complexes exhibit improved 
antioxidant activity as enzyme mimics19,20. 
 
Curcumin metabolites, degradation products, and synthetic 
analogues 
Turmeric contains three curcumin analogues, 
curcumin, demethoxycurcumin (DMC), and 
bisdemethoxycurcumin (BDMC), collectively known 
as curcuminoids (Scheme 1)1-7. The three compounds 
differ in substitution on the aromatic ring, while 
curcumin has two symmetric o-methoxy phenols 
 
Scheme 1 — Important chemical constituents of turmeric extract 
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linked through the , -unsaturated -diketone 
moiety, BDMC, also symmetric but lacks in two o-
methoxy substitutions, and DMC has an asymmetric 
structure with only one o-methoxy substitution. Of the 
three curcuminoids, curcumin is the most abundant in 
turmeric, followed by DMC and BDMC. A lesser 
known curcuminoid from turmeric is cyclocurcumin. 
Both DMC and BDMC have also been reported to 
exhibit biological activities. 
Metabolism of curcumin produced partially and 
fully reduced and conjugated derivatives,  
which include, dihydrocurcumin (DHC), 
tetrahydrocurcumin (THC), hexahydrocurcumin 
(HHC), octahydrocurcumin (OHC), curcumin 
glucuronide, and curcumin sulfate (Scheme 2)4,7,21. 
THC, a partially reduced derivative of curcumin, is one 
of the major metabolites of curcumin and has also been 
studied extensively. THC shows excellent antioxidant 
activity. Other reduced forms of curcumin, HHC and 
OHC, have not been examined as extensively as THC. 
The degradation products of curcumin are trans-6-(4-
hydroxy-3-methoxyphenyl)-2,4,-dioxo-5-hexenal (major 
products), vanillin, ferulic acid and feruloylmethane 
(Scheme 2). All these products have been reported to 
exhibit biological activities4,22. 
Structurally, curcumin has three important 
functionalities, which can be synthetically modified. 
These are an aromatic o-methoxy phenolic group, ,  
β unsaturated diketo moiety and a seven carbon linker. 
The o-methoxyphenol group and methylenic hydrogen 
are responsible for the antioxidant activity of curcumin, 
and curcumin donates an electron/hydrogen atom to 
ROS4,7. While the phenolic OH is essential for ROS 
scavenging, the diketone moiety is necessary for its 
biological activity. Additionally diketone moiety is 
involved in its degradation and hydrolysis and also for 
chelation reaction with many metal ions4,7,15,19,22.  
To overcome the problem of fast degradation and 
to improve the anti-tumor activity of curcumin, new 
synthetic derivatives have been made and studied 
extensively in the literature4,23-26. Essentially three 
main modifications were reported. In the first 
category, the basic structural features of curcumin, are 
retained and a slight modification in the three above 
mentioned functionalities were carried out. In the 
second group, these analogues have structural 
 
 
Scheme 2 — Important metabolic and degradation products of curcumin 
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similarity but do not have basic curcumin skeleton. 
The third category of compounds is metal complexes 
of curcumin and its analogues. The number of reports 
on the second and third groups is vast and outnumber 
the first group and is not included in this article. In the 
first category, our group has undertaken research on 
methylated curcumin analogue, known as dimethyl 
curcumin (DIMC), where the phenolic OH groups are 
converted to methoxy groups. DIMC did not show 
ROS scavenging activity but was found to exhibit better 
anti-tumor activity than curcumin27,28. We have also 
undertaken studies on pyrazole and isoxazole derivatives 
of curcumin, where the diketo group converted to more 
electron rich groups. These compounds showed less 
degradation and exhibited interesting physico-chemical 
properties17. Finally hispolon (HS), which is also a 
natural curcumin analogue, having similarity to half 
curcumin is also investigated for antioxidant and 
anticancer activities29. Results from these three different 
types of analogues (as shown in Scheme 3) were 
compared with those from curcumin and included in this 
manuscript for discussion.  
 
Comparative cytotoxicity studies of curcumin and DIMC in 
cancer cells  
DIMC is the metabolically stable derivative of 
curcumin25. The phenolic hydroxyl moiety of the 
curcumin is susceptible to the glucuronidation and 
sulphonation reactions during hepatic metabolism in 
the body4,14,21,22. Since DIMC has phenolic hydroxyl 
moiety replaced with methoxy group, it shows 
remarkable resistance against hepatic metabolism. 
There are only a few reports in the literature on the 
comparison of the biological activity of DIMC and 
curcumin26,27,30. On similar lines, our group has 
previously compared the cytotoxicity, cellular uptake 
and prooxidant activities of curcumin and DIMC in 
human breast carcinoma (MCF-7) cells27,31 (Table 1).  
In brief, human breast carcinoma cells (MCF-7) were 
treated with equimolar concentration (10 μM, 48 h) of 
curcumin and DIMC and the viability was determined 
by MTT assay. Notably, both curcumin and DIMC 
displayed comparable cytotoxicity (~30%). 
Subsequently to understand the mechanism of 
cytotoxicity, the cellular uptake and pro-oxidant 
activities of curcumin and DIMC were studied in 
MCF-7 cells28,31. The pro-oxidant activity of curcumin 
and DIMC was measured in terms of their abilities to 
modulate cellular levels of ROS as well as GSH. The 
ROS and GSH estimation was done by using standard 
fluorometric assays (2,7-Dichlorofluoresc in diacetate 
(DCFDA) and o-phthalaldehyde, respectively)32,33. 
This analysis indicated that treatment with either 
curcumin or DIMC led to a concentration dependant 
increase in the production of ROS and a concurrent 
decrease in GSH. At equimolar concentration (10 μM 
for 2 h) both curcumin and DIMC showed ~3 fold 
induction in basal ROS level28,31. Further, cellular 
uptake of curcumin and DIMC in cells was estimated 
by following their absorbance at ~420 nm in cellular 
lysate as described in our previous reports34,35. The 
cellular uptake of curcumin or DIMC was normalized 
 
Scheme 3 — Chemical structure of curcumin and hispolon 
derivatives studied in our laboratory 
Table 1 — Comparative cytotoxicity and pro-oxidant  
activity of curcumin and hispolon derivatives in  
human breast carcinoma (MCF-7) cells24,27.  
Values are mean ± SEM (n=3) 
Compounds Cytotoxicity 
(MTT assay) 
Treatment condition  
(10 µM for 48 h) 
ROS generation 
(DCFDA assay) 
Treatment condition  
(10 µM for 2 h) 
Curcumin 28±4% ~ 3 folds 
DIMC 35 ±3% ~3 folds 
CI 42±5% ~1.5 folds 
CP 38±2% ~1.5 folds 
HS 30±3% No significant increase 
HME 33 ± 5% No significant increase 
HP 2.0 ±0.12% No significant increase 
HMEP 29 ±3% No significant increase 
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to cell number or the protein content. From these 
studies, it was found that cellular uptake of curcumin 
(44.2 ± 7.2 pmoles/million) in MCF-7 cells was 
marginally higher as compared to that of DIMC  
(37.6 ± 5.6 pmoles/million cells)25,28,31,32. Subsequently, 
similar parameters of curcumin and DIMC were 
determined  in  human  lung  carcinoma  (A549) cells.  
The results indicated that DIMC exhibited ~ 3 folds 
higher (52%) cytotoxicity as compared to that of 
curcumin (16 %) at an equimolar concentration  
(10 µM for 48 h) of treatment (Fig. 1A). On the 
contrary DIMC exhibited ~1.5 folds lesser cellular 
uptake (~ 220 ng of DIMC/mg of cellular protein) as 
compared to that of curcumin (~390 ng of 
curcumin/mg of cellular protein) in this cell line36,37. 
The ROS generation by curcumin and DIMC in A549 
cells was comparable to each other (Fig. 1B). From 
these studies, it appears that the phenolic hydroxyl  
or methoxy group does not play any role in the  
pro-oxidant activity of these compounds in the tumor 
cells as both of these compounds behaved similarly in 
terms of ROS generation. A second important finding 
of the above observations is that despite having lower 
uptake by cells, DIMC exhibits either comparable or 
higher toxicity than curcumin. One of the 
explanations for this could be the presence of a 
methyl group in the ring structure of DIMC increasing 
its chemical and metabolic stability of DIMC over 
curcumin. It is also likely that curcumin and DIMC 
may be differentially regulating signalling proteins 
like NF-κB, thioredoxin reductase (TrxR) and DNA 
repair pathways that need to be investigated30. The 
lower cellular uptake of DIMC could be due to its 
higher hydrophobicity as compared to curcumin. 
Further to establish the selective cytotoxicity of 
curcumin derivatives towards cancer cells, our group 
has also reported the cytotoxicity of curcumin and 
DIMC in normal cells such as murine splenic 
lymphocytes by MTT assay28. The results of this 
study indicated that both curcumin and DIMC caused 
concentration dependant cytotoxicity in spleen 
lymphocytes. However, when compared at equimolar 
treatment concentration (10 μM), the percent 
cytotoxicity caused by curcumin and DIMC in splenic 
lymphocytes was significantly lower as compared to 
those observed in MCF-7 and A549 cells28. This 
suggested the differential cytotoxicity of curcumin 
and DIMC in normal versus tumor cells.  
 
Comparative cytotoxicity studies of isoxazole and pyrazole 
derivatives of curcumin in cancer cells 
As discussed in the previous sections, the ,  
-unsaturated diketone group present in the structure 
of curcumin has been linked with its anticancer 
activity as well as instability under physiological 
conditions4,7. For example, several reports have 
established that ketone group of curcumin acts as a 
Michael acceptor and therefore can form adducts 
(covalent modification) with the thiol (-SH), groups 
containing bio-molecules such as GSH and signalling 
proteins4,21,22,38. During this process, curcumin 
generates ROS as well as affects the functionality of 
several signalling proteins leading to apoptosis. Based 
on these studies, several researchers have synthesized 
curcumin derivatives by a conjugating β-diketo group 
with pyrazole (CP) or isoxazole (CI) group and have 
demonstrated the change in its anticancer 
activities26,39,40. These reports together indicated that 
CP and CI derivatives exhibited higher cytotoxicity 
compared to curcumin in cancer cell lines. In 
continuation of these reports, here we have compared 
the cytotoxicity of curcumin with its CP and CI 
derivatives in A549 cells under identical treatment 
 
 
Fig. 1 — The cytotoxic effect of curcumin and hispolon 
derivatives in human lung carcinoma (A549) cells at equimolar 
concentration (10 µM) after (A) 48 h of treatment by MTT assay; 
and (B) 2 h of treatment by DCFDA assay. Values are mean ± 
SEM (n = 3) 
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conditions (10 µM for 48 h) by MTT assay. Notably, 
the cytotoxicity of curcumin derivatives followed the 
order CI> CP > curcumin (Fig. 1A). A similar trend 
of cytotoxicity has been reported in MCF-7 cells  
(Table 1). About pro-oxidant activity, both CI and CP 
did not induce any significant ROS generation in 
A549 cells under equimolar treatment condition  
(10 µM for 2 h) by DCFDA assay (Fig. 1B). From 
these results, it is clear that the enhanced toxicity of 
CI and CP is not due to their pro-oxidant activity. 
Previously researchers have reported that the diketo 
moiety of curcumin interacts with cellular proteins not 
only through Michael addition reaction but also by 
involving non covalent interactions41. The conjugation 
of diketo group of curcumin with electron rich 
moieties like pyrazole and/or isoxazole is expected to 
enhance its interaction with cellular proteins and thus 
can enhance its cytotoxicity in tumor cells; however, 
this hypothesis needs to be validated in future38. The 
decrease in the pro-oxidant activity of CI and CP as 
compared to curcumin is attributed to the 
unavailability of free ketone group which is 
responsible for their reactivity towards cellular 
thiol4,38. Finally, there are no reports on the cellular 
uptake of CP and CP derivatives and therefore it 
would be interesting in the future to correlate their 
cytotoxic effects in tumor cells with cellular uptake. 
 
Comparative cytotoxcity studies of HS derivatives with 
curcumin in cancer cells 
As discussed in the introduction section, HS is 
another important natural product which is structurally 
similar to curcumin29. This compound per se has been 
reported for various pharmacological activities like 
anti-inflammatory, anticancer, antioxidant and anti-
bacterial among others42-45. Encouraged by these 
reports, our group has recently established the 
structure activity correlation of various HS derivatives 
(Scheme 3)29,46. In this study, four derivatives namely 
HS, hispolonpyrazole (HP), hispolonmonomethyl ether 
(HME), and hispolonmonomethyl ether pyrazole 
(HMEP) were evaluated in detail for chemical stability 
and cytotoxic effects in tumor cells29. The chemical 
stability of HS derivatives was found in the order of 
HS<HP~HME<HMEP29. The instability of HS is 
attributed to the auto-oxidation of phenolic hydroxyl 
group as well as hydrolysis of the conjugated diene 
structure. Accordingly substituting phenolic hydroxyl 
group with methoxy group in the ring structure of 
HME and blocking the diketo group with pyrazole 
group in HMEP increased the stability of hispolon 
derivatives. Similar observations have been reported 
previously with curcumin justifying our results4. 
Further, cytotoxicity of HS derivatives was evaluated 
in cancer cells including A549 and MCF-7 and in 
murine splenic lymphocytes representing normal cell 
type (Fig. 1 & Table 1). Notably, all four HS 
derivatives exhibited lower cytotoxicity as compared to 
curcumin in tumor cells. Among HS derivatives, HME 
exhibited higher toxicity followed by HS in tumor cells 
at equimolar treatment conditions (10 µM for 48 h) 
(Fig. 1 & Table 1). The compounds, HP and HMEP 
wherein the diketo moiety is conjugated with pyrazole 
group showed lesser toxicity compared to respective 
parent compounds HS and HME under similar 
treatment conditions (Fig. 1 & Table 1). Comparing the 
cytotoxic effect of HS derivatives in splenic 
lymphocytes with those in MCF-7 and A549 cells, it 
was observed that only HS exhibited selective 
cytotoxicity towards tumor cells29. The mechanistic 
investigations suggested that modulation of 
intracellular redox status coupled with the inhibition of 
intracellular TrxR activity is one of the factors 
responsible for the cytotoxic effect of HS derivatives in 
tumor cells29. For example, HS per se induced mild 
oxidative stress in MCF-7 cells by increasing ROS 
generation and decreasing GSH level (Fig. 1B). On the 
other hand, HME, HP and MHEP showed induction of 
reductive environment (lower ROS level) within cells 
by affecting the utilization-recycling pathway of GSH 
(Fig. 1B). Further TrxR is a very important intracellular 
redox enzyme responsible for DNA synthesis and 
maintaining reductive environment in reduced state29. 
The inhibition or decrease in the activity of TrxR is 
reported to cause anti-proliferative effects and/or 
cytotoxicity. The enzyme kinetics and in silico analysis 
indicated that HME was the strongest inhibitor of TrxR 
followed by HS and respective pyrazole derivatives 
such as HMEP and HP29. Together these results 
indicated that replacing phenolic hydroxyl with 
methoxy group and /or conjugating pyrazole moiety 
with the diketo group in HS changes its behaviour from 
pro-oxidant to antioxidant nature in cells29,46. 
Additionally, diketo moiety of HS plays an important 
role in its interaction with cellular protein like TrxR29. 
It would be interesting in the future to understand the 
interaction of HS derivatives with other important 
cellular proteins. 
 
Conclusions 
The studies reported on various structural 
modifications of curcumin indicated that its diketo 
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moiety regulates the redox moldulatory activity. 
Additionally, diketo moiety is also responsible for the 
interaction of curcumin with cellular proteins. Since 
the anticancer activity of curcumin derivatives has 
mainly been attributed to their redox modulatory 
behaviours as well as the ability to interact with 
various signalling proteins, the structural modification 
of diketo moiety is expected to increase its activity. 
Indeed isoxazole and pyrazole substitutions at the 
diketo moiety of curcumin have shown an increase in 
its anticancer potential. Further, methoxy substitution 
in the phenolic moiety of curcumin has also shown a 
very significant increase in its anticancer activity. 
However, most of these results have come from  
in vitro studies and need to be validated in animal 
models. Taken together, it is concluded that specific 
structural modifications on curcumin can be adopted 
as a tool to fine tune its anticancer activity.  
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